OptimizeRx
OptimizeRx's revenue rose 18.8% to $109 million in fiscal 2025. Its operating margin was 10.7%, up from −14.9% a year earlier. Free cash flow was $19 million, up 290.6%. The diluted share count rose 3.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2018 to 2025, earnings per share grew 45.0% a year and net income 58.8% a year, as new shares raised the share count by 60% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 85 | 74 | — | 13 | 23 |
| Debt incl. finance leases | — | — | 38 | 34 | 26 |
| Net debt (negative means net cash) | — | — | — | 21 | 3 |
| Net debt to EBITDA | — | — | — | — | 0.2x |
| Debt to equity | — | — | 0.3x | 0.3x | 0.2x |
| Interest coverage | — | — | −18.2x | −2.2x | 2.2x |
| Current ratio | 12.3x | 11.7x | 3.0x | 2.9x | 3.0x |
| Quick ratio | 12.3x | 11.7x | 3.0x | 2.9x | 3.0x |
Cash flow
Projections
Project OptimizeRx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What OptimizeRx says to expect
- Full year 2026: revenue and adjusted EBITDA
The Company is updating its fiscal year 2026 guidance, and now expects revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought OptimizeRx shares on the open market, and 1 insider sold $18,752.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | Edward StelmakhChief Finance & Strat Officer | Sold | 1,388 | $13.51 | $18,752 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 5 of 9 | 8 of 9 |
| Rule of 40 | 4.3% | 34.0% | 35.8% |
| Altman Z'' | 1.53 | 1.48 | 3.37 |
| Accruals ratio | −6.5% | −14.1% | −7.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | 5 of 9 | 8 of 9 |
Compare
Put OptimizeRx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | |
| CareCloud | FY25 | 8.7% | 9.4% | 19.7% | 21.5% | −0.1x | 5 | Compare |
| NRC Health | FY25 | −4.0% | 16.4% | 11.5% | 16.4% | 2.5x | 5 | Compare |
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 8 | 12 | 21 | 25 | 43 | 61 | 62 | 72 | 92 | 109 |
| Revenue growth | 7.3% | 56.5% | 74.9% | 16.0% | 76.1% | 41.5% | 1.9% | 14.5% | 28.8% | 18.8% |
| Gross profit | 4 | 6 | 12 | 15 | 24 | 36 | 39 | 43 | 59 | 74 |
| Research and development | — | — | 0 | 2 | 0 | — | — | — | 0 | 0 |
| Operating income | −2 | −2 | 0 | −4 | −2 | 0 | −12 | −26 | −14 | 12 |
| Net income | −2 | −2 | 0 | −3 | −2 | 0 | −11 | −18 | −20 | 5 |
| Diluted EPS (US$) | −0.15 | −0.21 | 0.02 | −0.23 | −0.15 | 0.02 | −0.64 | −1.03 | −1.10 | 0.27 |
| Diluted shares (millions) | 10 | 10 | 12 | 13 | 15 | 18 | 18 | 17 | 18 | 19 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −2 | 1 | −2 | −6 | 1 | 11 | −7 | 5 | 19 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −1 | −2 | 1 | −2 | −6 | 1 | 11 | −7 | 5 | 19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 1 | 0 | 0 | 0 | 0 | 0 | 20 | 8 | 0 | 0 |
| Acquisitions | 0 | 0 | 6 | 9 | 0 | 0 | 2 | 83 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 2 | 2 | 3 | 6 | 16 | 14 | 12 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 7 | 5 | 9 | 19 | 10 | 85 | 74 | — | 13 | 23 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 38 | 34 | 26 |
| Total assets | 12 | 10 | 25 | 57 | 60 | 141 | 135 | 183 | 171 | 177 |
| Total liabilities | 4 | 4 | 7 | 12 | 10 | 10 | 8 | 57 | 54 | 49 |
| Shareholders' equity | 8 | 6 | 18 | 45 | 50 | 131 | 126 | 127 | 117 | 128 |
| Margins and ratios | ||||||||||
| Gross margin | 56.0% | 49.1% | 57.6% | 62.8% | 55.6% | 58.1% | 62.4% | 60.0% | 64.5% | 67.2% |
| Operating margin | −20.4% | −17.6% | 0.8% | −15.0% | −4.9% | 0.6% | −19.7% | −36.9% | −14.9% | 10.7% |
| Net margin | −19.9% | −17.4% | 1.1% | −12.8% | −5.1% | 0.6% | −18.3% | −24.6% | −21.8% | 4.7% |
| Free cash flow margin | −8.3% | −12.6% | 3.6% | −7.1% | −14.7% | 1.0% | 16.9% | −10.2% | 5.2% | 17.1% |
| Rule of 40 (growth + FCF margin) | −1.0% | 43.9% | 78.4% | 8.9% | 61.4% | 42.5% | 18.8% | 4.3% | 34.0% | 35.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | 6.4% |
| Return on equity | −18.4% | −30.0% | 1.8% | −9.9% | −4.7% | 0.4% | −8.9% | −13.9% | −16.5% | 4.2% |
| Return on assets | −12.9% | −19.8% | 1.3% | −7.7% | −3.8% | 0.4% | −8.3% | −11.1% | −11.3% | 3.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | 0.2x |